Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma

Pancreatology

Volumn 15, Issue 6, 2015, Pages 667-673

  Khushman, Moh'D ^a   Dempsey, Naomi ^a   Cudris Maldonado, Jennifer ^b   Loaiza Bonilla, Arturo ^c   Velez, Michel ^d   Carcas, Lauren ^e   Dammrich, Daniel ^a   Hurtado Cordovi, Jorge ^a   Parajuli, Ritesh ^a   Pollack, Terri ^a   Harwood, Ana P ^a   Macintyre, Jessica ^a   Tzeng, Ching Wei D ^f   Merchan, Jaime R ^a   Restrepo, Maria H ^a   Akunyili, Ikechukwu I ^a   Ribeiro, Afonso ^a   Narayanan, Govindarajan ^a   Portelance, Lorraine ^a   Sleeman, Danny ^a   Levi, Joe U ^a   Rocha Lima, Caio M S ^a   Hosein, Peter J ^f   more..

^a UNIVERSITY OF MIAMI   (United States)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Memorial Cancer Institute   (United States)

^e Florida Cancer Care   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Borderline resectable pancreatic cancer; Chemotherapy; FOLFIRINOX; Locally advanced pancreatic cancer; Neoadjuvant; Pancreatic adenocarcinoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTINUOUS INFUSION; DIARRHEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; MIDDLE AGED; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84962208346     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2015.08.010     Document Type: Article

References (28)

1. Cancer facts & figures 2014 American Cancer Society
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin 2010 60 2010 277 300
3. M.P. Callery, K.J. Chang, E.K. Fishman, M.S. Talamonti, L. William Traverso, and D.C. Linehan Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement Ann Surg Oncol 16 2009 1727 1733
4. C.A. Iacobuzio-Donahue, B. Fu, S. Yachida, M. Luo, H. Abe, C.M. Henderson, and et al. Dpc4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813
5. S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, H. Friess, and J. Kleeff Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 2010 e1000267
6. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, Y. Becouarn, and et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
7. K.S. Gunturu, X. Yao, X. Cong, J.R. Thumar, H.S. Hochster, S.M. Stein, and et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity Med Oncol 30 2013 361
8. L. Marthey, A. Sa-Cunha, J.F. Blanc, M. Gauthier, A. Cueff, E. Francois, and et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an ageo multicenter prospective observational cohort Ann Surg Oncol 22 2015 295 301
9. J.E. Faris, L.S. Blaszkowsky, S. McDermott, A.R. Guimaraes, J. Szymonifka, M.A. Huynh, and et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts general hospital cancer center experience Oncologist 18 2013 543 548
10. M. Blazer, C. Wu, R.M. Goldberg, G. Phillips, C. Schmidt, P. Muscarella, and et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas Ann Surg Oncol 22 2015 1153 1159
11. B.A. Boone, J. Steve, A.M. Krasinskas, A.H. Zureikat, B.C. Lembersky, M.K. Gibson, and et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer J Surg Oncol 108 2013 236 241
12. P.J. Hosein, J. Macintyre, C. Kawamura, J.C. Maldonado, V. Ernani, A. Loaiza-Bonilla, and et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma BMC Cancer 12 2012 199
13. P.F. Peddi, S. Lubner, R. McWilliams, B.R. Tan, J. Picus, S.M. Sorscher, and et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma JOP 13 2012 497 501
14. K.K. Christians, S. Tsai, A. Mahmoud, P. Ritch, J.P. Thomas, L. Wiebe, and et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 19 2014 266 274
15. S.Y. Moorcraft, K. Khan, C. Peckitt, D. Watkins, S. Rao, D. Cunningham, and et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience Clin Colorectal Cancer 13 2014 232 238
16. F. Huguet, T. Andre, P. Hammel, P. Artru, J. Balosso, F. Selle, and et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase ii and iii studies J Clin Oncol 25 2007 326 331
17. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, and et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N. Engl J Med 369 2013 1691 1703
18. M.A. Tempero, M.P. Malafa, S.W. Behrman, A.B. Benson 3rd, E.S. Casper, E.G. Chiorean, and et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines J Natl Compr Cancer Netw: JNCCN 12 2014 1083 1093
19. H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, K. Ridwelski, and et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277
20. W.F. Regine, K.A. Winter, R.A. Abrams, H. Safran, J.P. Hoffman, A. Konski, and et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 2008 1019 1026
21. J.P. Neoptolemos, D.D. Stocken, C. Bassi, P. Ghaneh, D. Cunningham, D. Goldstein, and et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 2010 1073 1081
22. D.B. Evans, G.R. Varadhachary, C.H. Crane, C.C. Sun, J.E. Lee, P.W. Pisters, and et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 2008 3496 3502
23. G.R. Varadhachary, R.A. Wolff, C.H. Crane, C.C. Sun, J.E. Lee, P.W. Pisters, and et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head J Clin Oncol 26 2008 3487 3495
24. R. Kim FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 12 2011 8 9
25. P. Hammel, F. Huguet, J.L. Van Laethem, D. Goldstein, B. Glimelius, P. Artru, and et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase iii lap 07 study J Clin Oncol 31 2013 LBA4003
26. M.H. Katz, C.H. Crane, and G. Varadhachary Management of borderline resectable pancreatic cancer Semin Radiat Oncol 24 2014 105 112
27. S. Valeri, D. Borzomati, G. Nappo, G. Perrone, D. Santini, and R. Coppola Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? case report and review of the literature Pancreatol Off J Int Assoc Pancreatol 14 2014 425 430
28. C.W. Tzeng, A. Balachandran, M. Ahmad, J.E. Lee, S. Krishnan, H. Wang, and et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer HPB: Off J Int Hepato Pancreato Biliary Assoc 16 2014 430 438